Christophe Ferrand

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7237998/publications.pdf

Version: 2024-02-01

		752573	
19	765	14	20 g-index
papers	citations	h-index	g-index
22	22	22	1100
23	23	23	1129
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. British Journal of Haematology, 2009, 145, 624-636.	1.2	163
2	Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. Blood, 2004, 105, 1256-1264.	0.6	83
3	How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?. Blood Advances, 2019, 3, 4238-4251.	2.5	72
4	CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor–Engineered T Cells. Cancer Research, 2019, 79, 663-675.	0.4	62
5	Involvement and prognosis value of CD8 + T cells in giant cell arteritis. Journal of Autoimmunity, 2016, 72, 73-83.	3.0	56
6	Engineered IL-10 variants elicit potent immunomodulatory effects at low ligand doses. Science Signaling, 2020, 13, .	1.6	47
7	Preferential splenic CD8+ T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia. Blood, 2013, 122, 2477-2486.	0.6	42
8	Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis. Blood Advances, 2021, 5, 1540-1551.	2.5	35
9	IL-21–Induced MHC Class II+ NK Cells Promote the Expansion of Human Uncommitted CD4+ Central Memory T Cells in a Macrophage Migration Inhibitory Factor–Dependent Manner. Journal of Immunology, 2016, 197, 85-96.	0.4	30
10	CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm. Leukemia, 2020, 34, 3228-3241.	3.3	27
11	Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients. Journal of Translational Medicine, 2021, 19, 265.	1.8	20
12	Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch. Cancer Gene Therapy, 2021, 28, 1365-1375.	2.2	18
13	New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies. Experimental Hematology and Oncology, 2015, 5, 7.	2.0	17
14	Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics. Frontiers in Oncology, 2020, 10, 599933.	1.3	15
15	EZH2 and KDM6B Expressions Are Associated with Specific Epigenetic Signatures during EMT in Non Small Cell Lung Carcinomas. Cancers, 2020, 12, 3649.	1.7	15
16	Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia., 2022, 10, e004222.		14
17	How should chimerism be decoded?1. Transplantation, 2003, 75, 50S-54S.	0.5	11
18	Systematic donor blood qualification by flow cytometry would have been able to avoid CLLâ€type MBL transmission after unrelated hematopoietic stem cell transplantation. European Journal of Haematology, 2012, 88, 269-272.	1,1	9

#	#	Article	IF	CITATIONS
1	L9	Potential added value of a RT-qPCR method of SOX 11 expression, in the context of a multidisciplinary diagnostic assessment of B cell malignancies. Experimental Hematology and Oncology, 2018, 7, 5.	2.0	2